Hyalex Orthopaedics Secures $33M Series A Financing to Advance Novel Synthetic Cartilage Replacement for Osteoarthritis Treatment

VCBeat (WeChat Official Account: vcbeat) learned from foreign media that on March 29, U.S. local time, medical device company Hyalex Orthopaedics completed a $33 million Series A financing round. The funds from this round will be used to support the company’s further research and development of polymers capable of replacing human cartilage.

It is reported that this round of financing was jointly invested by Strategic Healthcare Investment Partners and DSM Venturing.

Hyalex Orthopaedics is a Boston-based medical device startup focused on developing new products leveraging its HYALEX™ synthetic material technology. Backed by a research and leadership team with over a decade of experience in orthopedics, Hyalex Orthopaedics is poised to develop a novel therapy for osteoarthritis by replacing cartilage with HYALEX™ synthetic material in joint surgeries.

Hyalex Orthopaedics has developed a breakthrough synthetic biomaterial, HYALEX™, leveraging technology licensed from Stanford University. HYALEX™ mimics the structure and function of human hyaline cartilage, which connects joints such as the hip, knee, shoulder, and ankle. Unlike other polymers, HYALEX™ possesses the unique ability to maintain low friction and low wear under high-load conditions encountered in human joints.

Historically, patients with osteoarthritis could undergo joint replacement surgery to alleviate their condition, but this procedure has significant limitations. Although joint replacement is a viable option for many patients experiencing joint degeneration, younger patients may encounter certain restrictions in their daily activities post-surgery and might face the need for revision joint surgery in the future. The HYALEX™ synthetic material developed by Hyalex Orthopaedics offers a minimally invasive treatment for osteoarthritis and holds great potential in managing this condition.

“HYALEX™ synthetic materials can replace damaged cartilage in joints, providing bone protection and anatomical solutions for disease states such as osteoarthritis or cartilage injuries,” said Mira Sahney, President and CEO of Hyalex Orthopaedics. “Our vision is to leverage the properties of HYALEX™ to replace arthritic cartilage while preserving the body’s healthy bone.”

“HYALEX™ technology maintains extremely low wear characteristics under high loads,” said Lampros Kourtis, Founder and Chief Technology Officer of Hyalex Orthopaedics. “We will fully leverage the proceeds from this financing to advance our new technology, with the aim of bringing HYALEX™ to market as soon as possible.”

Strategic Healthcare Investment Partners is a U.S.-based venture capital firm. Strategic Healthcare Investment Partners focuses on investing in companies in the fields of medical devices, medical technology, and digital health.

DSM Venturing, established in 2001, serves as an external enabler of open innovation in the healthcare sector and has invested in more than 50 emerging innovative companies across the United States, Europe, and Israel. DSM Venturing aims to create a better life for all by leveraging science to deliver higher-quality healthcare services for current and future generations.

(Compiled by Liu Yujing)